Srijita Dhar

Srijita Dhar is a Senior Research Scientist at Prelude Therapeutics, with a focus on high-throughput RNAi screening and DNA damage repair in human cancer and rare diseases. Currently serving as a Guest Section Editor for Elsevier, Srijita has a strong background in molecular biology and genetics established during a postdoctoral fellowship at the National Institutes of Health (NIH). Academic achievements include a PhD in Biomedical Sciences from the University of Missouri, emphasizing receptor-mediated interactions of glycated proteins, and a Master's in Molecular Biology from the same institution. Educational credentials also feature a Bachelor's in Microbiology from Bangalore University.